Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2009

01-03-2009 | Case Report

Prolonged response to gefitinib in bone metastasis

Authors: Hiroaki Satoh, Hiroichi Ishikawa, Gen Ohara, Norihiro Kikuchi, Kiyohisa Sekizawa

Published in: Medical Oncology | Issue 1/2009

Login to get access

Excerpt

Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, and is regarded as a safe agent, although some toxic effects such as interstitial pneumonia exist [1, 2]. Gefitinib is now being attempted for patients with advanced non-small cell lung cancer (NSCLC). We herein report a lung adenocarcinoma patient who obtained regression of bone metastasis by gefitinib therapy. …
Literature
1.
2.
3.
Hawighorst H, Gademann G. Cure in a patient with multiple osseus metastases in non-small cell lung cancer: a case report. Strahlenther Onkol. 1993;169:617–20.PubMed
4.
Hirano Y, Oda M, Tsunezuka Y, Ishikawa N, Watanabe G. Long-term survival cases of lung cancer presented as solitary bone metastasis. Ann Thorac Cardiovasc Surg. 2005;11:401–4.PubMed
5.
Andritzky B, et al. Long-term survival after second-line therapy with docetaxel and carboplatin and monthly pamidronic acid in a woman with metastatic non-small cell lung cancer. Onkologie. 2006;29:206–8. doi:10.​1159/​000092263.PubMedCrossRef
6.
Metadata
Title
Prolonged response to gefitinib in bone metastasis
Authors
Hiroaki Satoh
Hiroichi Ishikawa
Gen Ohara
Norihiro Kikuchi
Kiyohisa Sekizawa
Publication date
01-03-2009
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 1/2009
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-008-9082-y

Other articles of this Issue 1/2009

Medical Oncology 1/2009 Go to the issue

Original Paper

Significance of p53 and CD31 in astrogliomas

Original Paper

Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin’s lymphoma in a patient with pituitary acromegaly

Original Paper

Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma

CASE

Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma

Case Report

Squamous cell carcinoma of the renal pelvis

Original Paper

Rituximab-induced acute thrombocytopenia: a case report and review of the literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits